NASDAQ:INSY

INSYS Therapeutics News Headlines

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.23
MA: $23,687,640.18
$65,799,000.00
52-Week Range N/A
VolumeN/A
Average Volume9.52 million shs
Market Capitalization$21.71 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21

Headlines

INSYS Therapeutics (NASDAQ INSY) News Headlines Today

SourceHeadline
Global Infantile Spasms Therapeutics Market 2020 Trending Technologies, Development Plans, Future Growth and Geographical Regions to 2025Global Infantile Spasms Therapeutics Market 2020 Trending Technologies, Development Plans, Future Growth and Geographical Regions to 2025
marketwatch.com - March 7 at 3:45 PM
Sublingual Sprays Sales Market Share, Application Analysis, Regional Outlook, Competitive Strategies, Key Players & Forecast up to 2026Sublingual Sprays Sales Market Share, Application Analysis, Regional Outlook, Competitive Strategies, Key Players & Forecast up to 2026
marketwatch.com - February 15 at 1:15 PM
Global Dravet Syndrome Thereapeutics Market Size By Production, Top Countries Import-Export And Consumption Forecast & Regional Analysis By 2026Global Dravet Syndrome Thereapeutics Market Size By Production, Top Countries Import-Export And Consumption Forecast & Regional Analysis By 2026
marketwatch.com - February 11 at 12:17 AM
Sublingual Sprays Market Share 2021 CAGR Status, Top Manufacturers, Analysis, Industry Size, Future Trends and Industry Growth Research Report 2026Sublingual Sprays Market Share 2021 CAGR Status, Top Manufacturers, Analysis, Industry Size, Future Trends and Industry Growth Research Report 2026
marketwatch.com - January 9 at 7:48 AM
Infantile Spasms Therapeutics Industry Market Report With Top Countries data, opportunities and growth Forecast to 2026 - MarketdeskInfantile Spasms Therapeutics Industry Market Report With Top Countries data, opportunities and growth Forecast to 2026 - Marketdesk
marketwatch.com - December 24 at 9:44 AM
INSYS Therapeutics, Inc. (NPR1.F)INSYS Therapeutics, Inc. (NPR1.F)
in.finance.yahoo.com - December 17 at 11:33 PM
Former Insys employee avoids jail for role in opioid kickback schemeFormer Insys employee avoids jail for role in opioid kickback scheme
reuters.com - December 2 at 8:23 PM
Holmdel Doc Recklessly Prescribed Opioids, Received Kickbacks: AGHolmdel Doc Recklessly Prescribed Opioids, Received Kickbacks: AG
msn.com - November 26 at 10:15 PM
PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of DirectorsPureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
businesswire.com - November 24 at 7:41 AM
Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of DirectorsVedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors
businesswire.com - November 24 at 7:41 AM
Global Infantile Spasms Therapeutics Market 2020 with Impact of COVID-19 Outbreak, SWOT Study, Steady Growth and Forecast 2025Global Infantile Spasms Therapeutics Market 2020 with Impact of COVID-19 Outbreak, SWOT Study, Steady Growth and Forecast 2025
marketwatch.com - September 29 at 7:33 PM
Two doctors, former Insys sales rep, charged over opioid kickback schemeTwo doctors, former Insys sales rep, charged over opioid kickback scheme
reuters.com - September 18 at 12:04 AM
Global Infantile Spasms Therapeutics Market 2020 Segmentation, Future Business Strategy, Manufacturers Analysis and Forecast by 2025Global Infantile Spasms Therapeutics Market 2020 Segmentation, Future Business Strategy, Manufacturers Analysis and Forecast by 2025
marketwatch.com - September 15 at 8:00 PM
Alabama doctors lose bulk of appeal in pill mill, Insys kickback convictionsAlabama doctors lose bulk of appeal in 'pill mill,' Insys kickback convictions
www.reuters.com - July 10 at 11:31 PM
Worldwide Infantile Spasm Treatment Market by 2024 Analysis, Opportunities, Challenges, Growth, Drivers, ManufacturersWorldwide Infantile Spasm Treatment Market by 2024 Analysis, Opportunities, Challenges, Growth, Drivers, Manufacturers
www.marketwatch.com - July 6 at 7:42 AM
Insys founder, ex-execs lose bid to duck prison pending opioid cases appealInsys founder, ex-execs lose bid to duck prison pending opioid case's appeal
www.reuters.com - July 2 at 12:03 AM
Infantile Spasm Treatment Market 2020 Global Trends, Market Share Size, Top Key Players, Regions, Countries and Forecast to 2025Infantile Spasm Treatment Market 2020 Global Trends, Market Share Size, Top Key Players, Regions, Countries and Forecast to 2025
www.marketwatch.com - June 27 at 1:40 PM
Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities LitigationKessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation
finance.yahoo.com - June 22 at 8:07 PM
Global Infantile Spasms Therapeutics Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2026Global Infantile Spasms Therapeutics Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2026
www.marketwatch.com - June 18 at 10:24 AM
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for AnaphylFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphyl
www.bloomberg.com - June 10 at 10:27 PM
Ex-Insys employee who testified against opioid makers execs ducks prisonEx-Insys employee who testified against opioid maker's execs ducks prison
www.reuters.com - June 10 at 10:27 PM
INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice InvestigationINSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation
www.bloomberg.com - May 26 at 11:24 PM
Ex-CFO of opioid maker Insys to settle investor claims for $2 millionEx-CFO of opioid maker Insys to settle investor claims for $2 million
www.reuters.com - May 26 at 11:24 PM
Substance Abuse Treatment Market Size Report 2020-2025: Future Trends and Industry Growth Research Report by Industry Research.coSubstance Abuse Treatment Market Size Report 2020-2025: Future Trends and Industry Growth Research Report by Industry Research.co
www.marketwatch.com - May 7 at 8:42 AM
Infantile Spasms Therapeutics Market 2020 With COVID-19 Impact Analysis, Business Opportunities and Future Outlook 2026Infantile Spasms Therapeutics Market 2020 With COVID-19 Impact Analysis, Business Opportunities and Future Outlook 2026
www.marketwatch.com - May 5 at 3:50 AM
Global Infantile Spasms Therapeutics Market 2020 Key Players, Regions, Company Profile, Growth Opportunity and Challenges by 2025Global Infantile Spasms Therapeutics Market 2020 Key Players, Regions, Company Profile, Growth Opportunity and Challenges by 2025
www.marketwatch.com - May 4 at 7:29 AM
Global Infantile Spasms Therapeutics Market Growth, Size, Share, Trends, Status and Forecast 2020-2026Global Infantile Spasms Therapeutics Market Growth, Size, Share, Trends, Status and Forecast 2020-2026
www.marketwatch.com - March 30 at 2:49 AM
INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular anINSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular an
www.bloomberg.com - March 29 at 9:48 PM
INSYS Therapeutics Adds Two New Executives to Senior Management TeamINSYS Therapeutics Adds Two New Executives to Senior Management Team
www.bloomberg.com - March 29 at 9:48 PM
Global Infantile Spasms Therapeutics Market 2020 Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2024Global Infantile Spasms Therapeutics Market 2020 Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2024
www.marketwatch.com - March 23 at 8:36 AM
Insys Therapeutics (INSY) - Options ChainInsys Therapeutics (INSY) - Options Chain
www.fool.com - March 22 at 10:44 PM
Opioid maker Insys founder cites coronavirus risk to avoid prisonOpioid maker Insys' founder cites coronavirus risk to avoid prison
www.reuters.com - March 20 at 6:05 PM
Opioid maker Insys founder owes $60 million to bribery scheme victimsOpioid maker Insys' founder owes $60 million to bribery scheme victims
www.reuters.com - March 13 at 8:50 PM
At 3.4% CAGR, Infantile Spasms Therapeutics Market Size, Growth Forecast Poised to Touch USD 163.7 million by 2025At 3.4% CAGR, Infantile Spasms Therapeutics Market Size, Growth Forecast Poised to Touch USD 163.7 million by 2025
www.marketwatch.com - March 3 at 9:30 AM
Insys founder should not alone pay victims restitution, judge saysInsys founder should not alone pay victims restitution, judge says
www.reuters.com - February 25 at 7:05 PM
Lennox-Gastaut Syndrome Drug Market Revenue and Investment Feasibility 2029 | Eisai Co Ltd, GW Pharmaceuticals Plc, INSYS Therapeutics IncLennox-Gastaut Syndrome Drug Market Revenue and Investment Feasibility 2029 | Eisai Co Ltd, GW Pharmaceuticals Plc, INSYS Therapeutics Inc
www.marketwatch.com - February 5 at 7:59 AM
Future of Infantile Spasm Treatment Market - A comprehensive study by Key Players: Insys Therapeutics, Orphelia PharmaFuture of Infantile Spasm Treatment Market - A comprehensive study by Key Players: Insys Therapeutics, Orphelia Pharma
www.marketwatch.com - January 30 at 7:53 AM
Insys Founder Seeks Delay for Prison Term to Appeal ConvictionInsys Founder Seeks Delay for Prison Term to Appeal Conviction
www.msn.com - January 29 at 2:11 PM
Detailed Analysis on Global Infantile Spasms Therapeutics Market Strong Growth, Analysis & Forecast 2029Detailed Analysis on Global Infantile Spasms Therapeutics Market Strong Growth, Analysis & Forecast 2029
www.benzinga.com - January 28 at 3:13 AM
Insys Founder, John Kapoor, Sentenced To 66 Months In Fentanyl Bribery CaseInsys Founder, John Kapoor, Sentenced To 66 Months In Fentanyl Bribery Case
www.forbes.com - January 24 at 10:01 PM
Former Insys exec John Kapoor gets 5 1/2 years for opioid schemeFormer Insys exec John Kapoor gets 5 1/2 years for opioid scheme
www.cnbc.com - January 23 at 10:15 PM
Insys Founder Gets 5½ Years in Prison in Opioid Kickback SchemeInsys Founder Gets 5½ Years in Prison in Opioid Kickback Scheme
www.nytimes.com - January 23 at 10:15 PM
Insys founder Kapoor sentenced to 66 months in prison for opioid schemeInsys founder Kapoor sentenced to 66 months in prison for opioid scheme
uk.reuters.com - January 23 at 5:15 PM
Insys Founder Gets 5 1/2 Years in Prison for Opioid FraudInsys Founder Gets 5 1/2 Years in Prison for Opioid Fraud
www.msn.com - January 23 at 5:15 PM
Insys Sales Chief Sentenced to 26 Months in Opioid-Fraud CaseInsys Sales Chief Sentenced to 26 Months in Opioid-Fraud Case
www.msn.com - January 23 at 5:15 PM
Insys Founder Gets 66 Months in Prison for Leading Opioid FraudInsys Founder Gets 66 Months in Prison for Leading Opioid Fraud
www.msn.com - January 23 at 5:15 PM
INSYS THERAPEUTICS FOUNDER JOHN KAPOOR SENTENCED TO 66 MONTHS IN PRISON FOR ROLE IN OPIOID FRAUD SCHEME - U.S. DISTRICT JUDGEINSYS THERAPEUTICS FOUNDER JOHN KAPOOR SENTENCED TO 66 MONTHS IN PRISON FOR ROLE IN OPIOID FRAUD SCHEME - U.S. DISTRICT JUDGE
www.cnbc.com - January 23 at 5:15 PM
Insys founder John Kapoor sentenced to 5 1/2 years for orchestrating opioid schemeInsys founder John Kapoor sentenced to 5 1/2 years for orchestrating opioid scheme
www.marketwatch.com - January 23 at 5:15 PM
Insys founder faces stiff prison sentence, $100 million-plus in forfeitureInsys founder faces stiff prison sentence, $100 million-plus in forfeiture
feeds.reuters.com - January 23 at 9:53 AM
Ex-pharma CEO gets over 2 years in prison for bribery schemeEx-pharma CEO gets over 2 years in prison for bribery scheme
finance.yahoo.com - January 22 at 7:57 PM
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.